Context Therapeutics Inc. (CNTX) Earnings Signals & AI Vibe Check

Latest Filing: 10-K  |  Filed Mar 23, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Context Therapeutics Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Context Therapeutics Inc.'s filing signal continuing negative.
earningsVibe SuperAnalyst™ Verdict: CONTINUING NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Continuing Negative
CLAUDE
Turned Negative
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Context Therapeutics Inc. actually do?
Answer:
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing T cell engaging (TCE) bispecific antibodies for solid tumors. The company's pipeline includes three lead product candidates: CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE; CT-95, a Mesothelin (MSLN) x CD3 TCE; and CT-202, a Nectin-4 x CD3 TCE. CTIM-76 is currently in a Phase 1 clinical trial, with interim data expected in June 2026, and CT-95 also began Phase 1 trials in April 2025, with interim data anticipated in September 2026. CT-202 is preparing for its first-in-human trial in Q3 2026. Context Therapeutics aims to advance these novel therapies to address significant unmet medical needs in oncology.
Question:
What are Context Therapeutics Inc.'s revenue drivers?
Answer:
The company has not generated any revenue from product sales and expects to continue incurring losses until its product candidates are successfully developed, approved, and commercialized.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required